Evommune, Inc. (EVMN)
Evommune, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Evommune, Inc. (EVMN) is a Biotechnology company based in US with a market capitalization of $173.1M. Revenue grew 85.7% year-over-year and free cash flow was negative at -$76.7M. This page tracks EVMN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 45 employees · IPO Nov 6, 2025
Valuation
Valuation & price
$22.92as of May 17, 2026· -27.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.84
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$173.1M
Market cap
85.7%
Revenue growth (YoY)
100.0%
Gross margin
-$76.7M
Free cash flow (USD)
-$147.1M
Net debt
Net cash position
4.8%
Share dilution
1/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2023 → 2025
Free cash flow by year
2023 → 2025
Gross margin by year
2023 → 2025
Value screen
Graham defensive-investor tests
2
Insider buys · 90 days
8
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 10, 2026Filing
Insider Buy $13KCarver Kyle · Chief Financial Officer · $13.3K
- Insider buyJul 8, 2026Filing
Insider Buy $133KKIRSCH ARTHUR S · Director · $133K
- 8-K eventJun 29, 2026Filing
Phase 2b Trial Results
- Insider sellJun 24, 2026Filing
Insider Sell $33K · 10b5-1 PlanPatel Jeegar Pravinkumar · Chief Scientific Officer · $33.5K
- Insider sellJun 24, 2026Filing
Insider Sell $453K · 10b5-1 PlanDrew Janice Suzann · Chief of Dev. Operations · $452.6K
- Insider sellJun 24, 2026Filing
Insider Sell $169K · 10b5-1 PlanPena Luis C. · Director, President & CEO · $168.9K
- Insider sellJun 3, 2026Filing
Insider Sell $382K · 10b5-1 PlanPena Luis C. · Director, President & CEO · $381.7K
- Insider sellJun 3, 2026Filing
Insider Sell $379K · 10b5-1 PlanPatel Jeegar Pravinkumar · Chief Scientific Officer · $379.5K
- Insider sellJun 3, 2026Filing
Insider Sell $123K · 10b5-1 PlanCohen David E · Director · $123.1K
- 8-K eventJun 2, 2026Filing
Annual Meeting Results
Questions
Frequently asked questions
What is Evommune, Inc.'s market cap?
Evommune, Inc. (EVMN) has a market capitalization of $173.1M.
What is EVMN's P/E ratio?
A meaningful P/E ratio is not available for EVMN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is EVMN's price-to-book (P/B) ratio?
EVMN trades at 0.84 times book value per share.
Are insiders buying EVMN stock?
Yes — SEC Form 4 filings show 2 open-market insider buys and 8 sells at Evommune, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.